MX2024009644A - Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada. - Google Patents
Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada.Info
- Publication number
- MX2024009644A MX2024009644A MX2024009644A MX2024009644A MX2024009644A MX 2024009644 A MX2024009644 A MX 2024009644A MX 2024009644 A MX2024009644 A MX 2024009644A MX 2024009644 A MX2024009644 A MX 2024009644A MX 2024009644 A MX2024009644 A MX 2024009644A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- hba1c
- weight loss
- glycosylated hemoglobin
- loss methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263307470P | 2022-02-07 | 2022-02-07 | |
| US202263382426P | 2022-11-04 | 2022-11-04 | |
| PCT/US2023/062065 WO2023150759A1 (en) | 2022-02-07 | 2023-02-06 | Methods of weight loss in a subject with elevated hba1c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009644A true MX2024009644A (es) | 2024-08-14 |
Family
ID=85569618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009644A MX2024009644A (es) | 2022-02-07 | 2023-02-06 | Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250134865A1 (https=) |
| EP (1) | EP4475842A1 (https=) |
| JP (1) | JP2025505632A (https=) |
| KR (1) | KR20240146053A (https=) |
| AU (1) | AU2023214495A1 (https=) |
| CA (1) | CA3243643A1 (https=) |
| IL (1) | IL314682A (https=) |
| MX (1) | MX2024009644A (https=) |
| WO (1) | WO2023150759A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3565806T (pt) | 2017-01-06 | 2022-05-19 | Rivus Pharmaceuticals Inc | Novos derivados de fenilo |
| WO2022246039A1 (en) * | 2021-05-20 | 2022-11-24 | Rivus Pharmaceuticals, Inc. | Methods of treating mitochondria-related disorders |
-
2023
- 2023-02-06 WO PCT/US2023/062065 patent/WO2023150759A1/en not_active Ceased
- 2023-02-06 US US18/835,578 patent/US20250134865A1/en active Pending
- 2023-02-06 IL IL314682A patent/IL314682A/en unknown
- 2023-02-06 JP JP2024546294A patent/JP2025505632A/ja active Pending
- 2023-02-06 CA CA3243643A patent/CA3243643A1/en active Pending
- 2023-02-06 KR KR1020247029814A patent/KR20240146053A/ko active Pending
- 2023-02-06 MX MX2024009644A patent/MX2024009644A/es unknown
- 2023-02-06 EP EP23710591.1A patent/EP4475842A1/en active Pending
- 2023-02-06 AU AU2023214495A patent/AU2023214495A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4475842A1 (en) | 2024-12-18 |
| WO2023150759A1 (en) | 2023-08-10 |
| IL314682A (en) | 2024-10-01 |
| AU2023214495A1 (en) | 2024-08-15 |
| US20250134865A1 (en) | 2025-05-01 |
| JP2025505632A (ja) | 2025-02-28 |
| KR20240146053A (ko) | 2024-10-07 |
| CA3243643A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ferrini et al. | CB 2 receptors regulate natural killer cells that limit allergic airway inflammation in a murine model of asthma | |
| Miyashita et al. | Adrenomedullin provokes endothelial Akt activation and promotes vascular regeneration both in vitro and in vivo | |
| WO1999066917A3 (en) | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid | |
| Takagi et al. | Recombinant human growth hormone modulates Th1 and Th2 cytokine response in burned mice | |
| Saiman et al. | Inhibition of the CXCL 12/CXCR 4 chemokine axis with AMD 3100, a CXCR 4 small molecule inhibitor, worsens murine hepatic injury | |
| BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
| AR063149A1 (es) | Formulaciones a base de polipeptidos estables | |
| DK1638586T3 (da) | Synergistisk sammensætning til behandling af diabetes mellitus | |
| Nakada et al. | Oral administration of geranylgeranylacetone improves survival rate in a rat endotoxin shock model: administration timing and heat shock protein 70 induction | |
| MX2009013779A (es) | Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r. | |
| JOP20210298A1 (ar) | طرق وتركيبات للوقاية من مرض السكري من النوع الأول | |
| MX2020008387A (es) | Usos terapeuticos de agonistas glp1r. | |
| Rossi et al. | Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society of Hypertension | |
| ATE348630T1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
| Suzuki et al. | Loss of hypoxia inducible factor‐1α aggravates γδ T‐cell‐mediated inflammation during acetaminophen‐induced liver injury | |
| BR112022007776A2 (pt) | Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína | |
| AR128257A1 (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting | |
| MX2024009644A (es) | Metodos de perdida de peso en un sujeto con hemoglobina glucosilada a1c (hba1c) elevada. | |
| IL274563B2 (en) | Methods of using and compositions containing dulaglutide | |
| FR2354101A1 (fr) | Preparation pour traiter les surcharges graisseuses et les infiltrats cellulitiques | |
| MX2022014586A (es) | Métodos y composiciones para tratar la fuga vascular. | |
| Song et al. | Modulation of endotoxin stimulated interleukin-6 production in monocytes and Kupffer cells by S-adenosylmethionine (SAMe) | |
| ATE277639T1 (de) | Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten | |
| ATE389183T1 (de) | Zytokapazität-verfahren | |
| MY103498A (en) | Dl-5-[(2-benzyl-3, 4-dihydro-2h-benzopyran-6-yl)methyl] thiazolidine-2, 4-dione as an anti-atherosclerosis agent |